CN117481905A - Eyeball accurate positioning support - Google Patents
Eyeball accurate positioning support Download PDFInfo
- Publication number
- CN117481905A CN117481905A CN202311548079.7A CN202311548079A CN117481905A CN 117481905 A CN117481905 A CN 117481905A CN 202311548079 A CN202311548079 A CN 202311548079A CN 117481905 A CN117481905 A CN 117481905A
- Authority
- CN
- China
- Prior art keywords
- eyeball
- support
- needle
- bracket
- syringe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000005252 bulbus oculi Anatomy 0.000 title claims abstract description 44
- 238000003780 insertion Methods 0.000 abstract description 8
- 230000037431 insertion Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- 210000001525 retina Anatomy 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000437273 Auricularia cornea Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038915 Retinitis viral Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F2009/0035—Devices for immobilising a patient's head with respect to the instrument
- A61F2009/0043—Devices for immobilising a patient's head with respect to the instrument by supporting the instrument on the patient's head, e.g. head bands
- A61F2009/0052—Devices for immobilising a patient's head with respect to the instrument by supporting the instrument on the patient's head, e.g. head bands the instrument being supported on the patient's eye
Abstract
The invention is suitable for the technical field of ophthalmic medical appliances, and provides an eyeball accurate positioning support, wherein the inner side wall of the support is attached to the limbus of a patient eyeball, and then two other positioning holes with certain distances on the support are needle insertion inlets, so that an injector can be positioned relatively quickly.
Description
Technical Field
The invention belongs to the technical field of ophthalmic medical appliances, and particularly relates to an eyeball accurate positioning support.
Background
Intravitreal drug injection, anti-VEGF drug injection for the treatment of wet AMD, diabetic retinopathy, and other ocular fundus vascular diseases; hormone preparations such as triamcinolone acetonide injection, dexamethasone injection and the like are injected. Injection of methotrexate for treatment of lymphomas; injecting marflange and topotecan to treat retinoblastoma; amphotericin B, fluconazole and voriconazole are injected to treat fungal endophthalmitis; ganciclovir and tolerability (sodium foscarnet) are used for treating viral retinitis. There is currently no uniform, authoritative quality control standard throughout the national ophthalmic industry, and there is no uniform consensus on some key issues related to injection procedures and quality (e.g., injection equipment and injection techniques, etc.). The increasing frequency of potential risks for treating retinopathy using intravitreal drug injection highlights the importance and urgency of quality control.
The treatment method comprises the following steps:
1. conventional superficial bulbar conjunctiva anesthesia may be performed, if necessary, with postbulbar blockage.
2. The eyelid was opened with an eyelid retractor and the conjunctival sac was rinsed with diluted gentamicin solution or diluted organic iodine solution.
3. The prepared medicine to be injected is extracted by a 1m1 syringe connected with a needle.
4. The eyeballs are fixed by toothed forceps, 3.5mm-4mm, 6-12 points (right eye) or 12-6 points (left eye) are behind the limbus, the eyeballs are penetrated by the injection needle to a depth of about 4mm-6mm, the needle points vertically to the center of the vitreous cavity, and then the liquid medicine is slowly injected. The needle tip direction should be avoided against the retina, especially the posterior macular portion. After the liquid medicine is injected, the needle head is quickly pulled out, and the needle eye is immediately pressed for 1min by the cotton swab.
5. Gentamicin 2 ten thousand U and dexamethasone 2.5mg are injected subconjunctival.
Existing intravitreal injection methods: when injecting the eyeball, need patient's cooperation, look at to a party, keep eyeball motionless, and then utilize the rule to measure the position of inserting the needle on the eyeball and at sclera surface nick location, because patient's eyeball turns to a party after, often unable longer time keeps eyeball fixed, and still need the back hand needle to find the needle position of inserting of the mark of nick on the sclera with the rule before again after positioning measurement, result in often need repeated measurement in order to confirm the position and the angle of inserting the needle, inefficiency, the length of syringe needle is different simultaneously, lead to inserting the needle degree of depth inequality, these all probably increase the risk of operation.
Disclosure of Invention
The invention provides an eyeball accurate positioning bracket, which aims to solve the problems that the existing vitreous cavity medicine injection method is low in efficiency and has potential risks in the actual operation process.
The invention realizes that the accurate eyeball positioning support is in a crescent shape, the whole of the support is in an arc shape and is attached to the surface of an eyeball, the crescent inner side of the support corresponds to the limbus of the eyeball, two positions which are vertically 3.5mm away from the crescent inner side wall and 4.0mm away from the outer side of the support are respectively provided with a positioning hole with an inclined angle and used for inserting an injector, and two ends of the support are respectively provided with an upward handle; the lower surface of the bracket is rough, and bumps used for pressing the parts of the syringe after being taken out are arranged near the two positioning holes.
Preferably, the thickness of the bracket is 1mm to 1.5mm, so as to limit the length of the needle of the syringe.
Compared with the prior art, the invention has the beneficial effects that: according to the accurate positioning bracket for the eyeball, the inner side wall of the bracket is attached to the cornea edge of the eyeball of a patient, and the other two positioning holes with the determined distance on the bracket are the needle insertion inlets, so that the injector can be positioned relatively quickly.
Drawings
FIG. 1 is a schematic diagram of the overall structure of the present invention;
FIG. 2 is a schematic view of a syringe according to the present invention;
FIG. 3 is a schematic view of a bracket structure according to the present invention;
FIG. 4 is a schematic cross-sectional view of a syringe according to the present invention;
FIG. 5 is a schematic view showing the position of the support on the eyeball according to the present invention;
FIG. 6 is a schematic view of the cross-sectional structure at D-D in FIG. 5;
in the figure: 1. a syringe; 11. a needle cylinder; 12. a piston rod; 13. a shoe; 14. a limit groove; 15. a half arc groove; 16. arrow mark; 2. a bracket; 21. positioning holes; 22. a handle; 23. a bump;
A. cornea; B. a limbus; C. sclera.
Detailed Description
The present invention will be described in further detail with reference to the drawings and examples, in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
Referring to fig. 1-6, the present invention provides a technical solution: an eyeball accurate positioning support is arranged in a crescent shape, the whole of the support is in an arc shape and is attached to the surface of an eyeball, the crescent inner side of the support corresponds to the limbus of the eyeball, two positions, which are vertically 3.5mm away from the crescent inner side wall and 4.0mm away from the outer side of the support, of the support are respectively provided with positioning holes for inserting an injector, and two ends of the support are respectively provided with an upward handle; the lower surface of the bracket is rough, and bumps used for pressing the parts of the syringe after being taken out are arranged near the two positioning holes.
According to the invention, the inner side wall of the bracket 2 is attached to the limbus of the eyeball of a patient, and the other two positioning holes 21 with a certain distance on the bracket 2 are needle insertion inlets, so that the syringe 1 can be positioned relatively quickly, the depth and the angle of the needle head section of the syringe 1 entering the inside of the vitreous cavity of the eyeball are fixed due to the thickness of the bracket 2, the situations that the lens or the peripheral retina is damaged when the needle head is inserted due to different depths of the needle head entering the eyeball and the deflection of the needle insertion angle are avoided when the needle head is injected, and meanwhile, the medicine outlet holes on the needle head are arranged on the peripheral side surface of the needle head section, so that the possibility that the traditional needle head injects the liquid medicine into the fundus retina, especially the hidden danger of injecting the retinal macula part, can be avoided, and meanwhile, the arrangement of the bracket 2 can also press and stop the needle insertion point when the syringe 1 is extracted, and the operation speed and efficiency of the surgical operation are improved.
Further; the liquid outlet of the needle head on the injector 1 is arranged on the side surface and is used for avoiding the damage to retina caused by direct injection to retina when the liquid medicine is injected.
Because the support 2 needs to be put into the eyeball of a patient, the support 2 needs to be disinfected at high temperature and high pressure, and then the support 2 needs to be made of high-temperature and high-pressure resistant materials, and meanwhile, when the support 2 is covered on the eyeball, the needle cannot be shielded, so that the operation vision is unclear, the support 2 needs to be transparent, and then the whole support 2 needs to be made of high-temperature and high-pressure resistant transparent glass, plastic or colloid and other materials.
The injector 1 comprises a needle cylinder 11 and a piston rod 12 which is inserted into the needle cylinder 11 in a drawing way, wherein a sliding foot 13 is arranged on the inner wall of the opening end of the needle cylinder 11, the sliding foot 13 slides in a notch on the outer wall of the piston rod 12 and is used for quantitatively limiting the piston rod 12, the notch comprises two limiting grooves 14 which are arranged at symmetrical positions on the outer wall of the piston rod 12 and are along the axial direction of the piston rod 12, and one ends of the two limiting grooves 14 are communicated through a half arc groove 15.
Typically, the process is repeated; the piston rod 12 is pushed to the inside of the needle cylinder 11 until the front end of the piston rod 12 is propped against the end of the inner end of the needle cylinder 11, then the piston rod 12 is rotated, so that the sliding feet 13 positioned in the half arc grooves 15 move along the half arc grooves 15, thereby moving from the upper end of one limit groove 14 to the upper end of the other limit groove 14, then the piston rod 12 is pulled outwards to extract the liquid medicine, and the sliding feet 13 on the needle tube slide along the limit groove 14 until sliding to the bottom of the limit groove 14, so that the piston rod 12 cannot be pulled upwards, and the quantitative extraction of the liquid medicine is realized.
The top of the piston rod 12 is provided with a large arrow mark 16 and a small arrow mark 16 which are respectively in one-to-one correspondence with the two 0.05ml limit grooves 14 and the 0.03ml limit grooves 14, and the open end of the needle cylinder 11 is provided with another arrow mark 16 corresponding to the sliding foot 13.
Specifically, the method comprises the following steps of; the large arrow mark 16 on the piston rod 12 corresponds to the position of the limit groove 14 of 0.05ml, the small arrow mark 16 corresponds to the position of the sliding foot 13, and therefore, when the piston rod 12 is rotated to enable the sliding groove to rotate in the half-arc groove 15 and rotate to the two ends, the arrow mark 16 on the needle is aligned with the large arrow mark 16 or the small arrow mark 16 on the piston rod 12 respectively, so that the surface sliding groove enters the upper end of the limit groove 14 corresponding to the arrow mark 16, and accordingly, the corresponding scale drawing can be carried out along the limit groove 14, the liquid medicine can be quantitatively extracted, the use of doctors is facilitated, and the problems that the data deviation is large and the treatment is influenced due to rough estimation are avoided.
Furthermore, it is provided that; the bracket 2 is crescent-shaped, and is integrally circular-arc-shaped and attached to the surface of the eyeball, and two ends of the bracket 2 are respectively provided with an upward handle 22; the crescent inner side of the bracket 2 corresponds to the cornea limbus of the eyeball, and two inclined positioning holes 21 for inserting the injector 1 are formed at two positions, 3.5mm and 4.0mm away from the cornea limbus, of the outer side of the bracket 2.
It should be explained that: the whole of the bracket 2 is arc-shaped and is attached to the surface of the eyeball, so that the curvature of the bracket is close to each other, the accuracy of the position during needle insertion is ensured, and the needle hole left after the syringe 1 is taken out is also convenient to perform compression hemostasis.
The positioning hole 21 is inclined at an angle perpendicular to the surface of the eyeball and biased to the direction far from the cornea, so that the distance of the needle entering the inside of the eyeball is shorter, and the liquid medicine is prevented from being irradiated onto the retina, thereby affecting the patient.
In addition, the method comprises the steps of; the support 2 is set to crescent, conveniently pastes the suitable configuration mutually to the inboard arc and the limbus outside of this support 2, then the doctor directly confirms the position of needle-in according to the position of two locating holes 21 on the support, avoids originally needing to carry out the certainty that the position was pricked to the sclera indentation through the rule, and this kind of mode inefficiency's problem of determining.
The two ends of the crescent are respectively provided with an upward handle 22, so that a user can conveniently take, put and adjust the bracket 2, and the height of the handle 22 is 5mm, and the diameter is 2mm.
The vitreous cavity of the eye is injected with the liquid medicine, and in order to ensure the safety of the needle head penetrating into the vitreous cavity, the needle is vertically inserted at a position 3.5mm or 4.0mm away from the limbus, so that the liquid medicine can be normally injected into the eyeball.
It should be noted that; the lower surface of the holder 2 is roughened, and projections 23 for pressing the portion of the syringe 1 after removal are provided near the two positioning holes 21.
The lower surface of support 2 sets up to coarsely to support 2 is difficult to slide on the eyeball surface, can be comparatively firm and stable laminating in patient's eyeball, guarantees the stability to syringe 1 support, is located near locating hole 21 and sets up a plurality of lugs 23 for after syringe 1 takes out, oppression after the hemorrhage point in the eyeball carries out the offset, avoids the hemorrhage point to last to bleed.
The holder 2 is provided with a thickness of 1mm to 1.5mm for defining a certain length of the needle of the syringe 1.
It should be noted that; in order to ensure the consistency of needle insertion of medicine injection every time, reduce the potential risk of retina and lens injury during operation, the bracket 2 needs to be provided with a certain thickness, and meanwhile, the positioning holes are obliquely designed, so that the length of the needle head which can finally enter the inside of an eyeball and the needle insertion angle are limited, the smooth injection of medicine liquid is ensured when the needle head is inserted into the inside of the vitreous cavity of the eyeball, and the aim of treatment is fulfilled.
The working principle and the using flow of the invention are as follows: after the invention is installed, firstly, a doctor rotates the piston rod 12 in the needle cylinder 11 into the corresponding limit groove 14 by confirming how much liquid medicine needs to be injected, then pushes the piston rod 12 to go deep into the needle cylinder 11, and then pulls out the piston rod 12 to extract the liquid medicine;
the patient is allowed to look in a certain direction and keep the eye position unchanged, then the crescent inner side of the bracket 2 is placed along the limbus, then the corresponding positioning hole 21 is selected, the injector 1 is inserted into the vitreous cavity of the eyeball along the inclined injection hole, the liquid medicine is injected into the vitreous cavity of the eyeball of the patient, then the injector 1 is pulled out outwards, then the bracket 2 is moved, and the bump 23 below the bracket 2 performs compression hemostasis on the bleeding point after the injector 1 is separated.
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, and alternatives falling within the spirit and principles of the invention.
Claims (2)
1. An eyeball accurate positioning support, its characterized in that: the support is in a crescent shape and integrally attached to the surface of an eyeball in an arc shape, the crescent inner side of the support corresponds to the limbus of the eyeball, two positions, which are vertically away from the crescent inner side by 3.5mm and 4.0mm, of the outer side of the support are respectively provided with a positioning hole for inserting the injector, and two ends of the support are respectively provided with an upward handle; the lower surface of the bracket is rough, and bumps used for pressing the parts of the syringe after being taken out are arranged near the two positioning holes.
2. An eyeball accurate positioning support according to claim 1 wherein: the thickness of the bracket is 1mm to 1.5mm, and the bracket is used for limiting the length of the needle head of the syringe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311548079.7A CN117481905A (en) | 2021-08-16 | 2021-08-16 | Eyeball accurate positioning support |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110936734.0A CN113476205B (en) | 2021-08-16 | 2021-08-16 | Injection device for injecting medicine into vitreous cavity of eyeball with accurate positioning and quantitative injection |
| CN202311548079.7A CN117481905A (en) | 2021-08-16 | 2021-08-16 | Eyeball accurate positioning support |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110936734.0A Division CN113476205B (en) | 2021-08-16 | 2021-08-16 | Injection device for injecting medicine into vitreous cavity of eyeball with accurate positioning and quantitative injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117481905A true CN117481905A (en) | 2024-02-02 |
Family
ID=77945443
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311548079.7A Pending CN117481905A (en) | 2021-08-16 | 2021-08-16 | Eyeball accurate positioning support |
| CN202110936734.0A Active CN113476205B (en) | 2021-08-16 | 2021-08-16 | Injection device for injecting medicine into vitreous cavity of eyeball with accurate positioning and quantitative injection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110936734.0A Active CN113476205B (en) | 2021-08-16 | 2021-08-16 | Injection device for injecting medicine into vitreous cavity of eyeball with accurate positioning and quantitative injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN117481905A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952109B (en) * | 2021-10-21 | 2024-03-22 | 成都米戈思医疗技术有限公司 | Eyeball fixing and auxiliary puncturing device |
| CN114983673B (en) * | 2022-07-20 | 2022-11-15 | 北京安龙生物医药有限公司 | Injection device for ophthalmic injection and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ496500A0 (en) * | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| CN102895731A (en) * | 2012-09-12 | 2013-01-30 | 广州军区广州总医院 | Injection device for vitreous chamber |
| CN208808830U (en) * | 2018-04-16 | 2019-05-03 | 温州医科大学 | A kind of ocular implantation material injection device |
| CN209137617U (en) * | 2018-10-17 | 2019-07-23 | 上海交通大学医学院附属第九人民医院 | A kind of accurate syringe of pen-holding type piston |
| CN211658492U (en) * | 2019-11-25 | 2020-10-13 | 王芬 | Syringe for injecting medicine into vitreous cavity |
| CN213552855U (en) * | 2020-10-19 | 2021-06-29 | 四川大学华西医院 | Vitreous body injection positioner and vitreous body injection assembly |
-
2021
- 2021-08-16 CN CN202311548079.7A patent/CN117481905A/en active Pending
- 2021-08-16 CN CN202110936734.0A patent/CN113476205B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113476205A (en) | 2021-10-08 |
| CN113476205B (en) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113476205B (en) | Injection device for injecting medicine into vitreous cavity of eyeball with accurate positioning and quantitative injection | |
| US11432962B2 (en) | Ocular treatment devices and related methods of use | |
| JP2020049361A (en) | Ab externo (from outside to inside the eye) intraocular shunt placement | |
| WO2007052730A1 (en) | Fixture for intravitreous injection | |
| CN105902341B (en) | Medicine-filling device under Tenon capsule | |
| US7879006B2 (en) | Injection aid for anterior juxtascleral depot | |
| CN207708079U (en) | Lacrimal embolism injector | |
| CN211433652U (en) | Device for implanting ophthalmic drainage tube | |
| CN211356212U (en) | Improved ophthalmic ball sub-fascia injection needle | |
| JP2023537962A (en) | Systems and methods for drug delivery to ocular tissue | |
| EP2564819A1 (en) | Intraocular injection device | |
| WO2023001244A1 (en) | Ophthalmic injection assembly and injection device, and use method | |
| RU2799076C1 (en) | Method of medicinal products administration into the suprachoroidal space | |
| CN211633872U (en) | Syringe capable of being accurately positioned | |
| CN215994480U (en) | Positioner for vitreous cavity injection | |
| US11819454B2 (en) | Intraocular injector | |
| CN214909111U (en) | Novel trace vitreous chamber medicine syringe | |
| CN207384376U (en) | A kind of ophthalmology silicone oil draw-out device | |
| GB2474646A (en) | Eye injection guide means | |
| CN102283741A (en) | Folding artificial vitreous body injector | |
| CN204337126U (en) | A kind of be used in eye socket, peribulbar and retrobulbar injection doser | |
| CN206315188U (en) | Medicine-filling device under Tenon capsules | |
| Agarwal et al. | Bi-Manual Phaco | |
| CN115414177A (en) | Simple vitreous cavity gas-liquid exchange technique | |
| RU2525512C1 (en) | Method of drug dilation of rigid pupil before performing phacoemulsification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |